The Cerebral Malaria Therapeutics Market report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size.
The global cerebral malaria therapeutics market has been segmented based on drug class, distribution channel, and region. In terms of drug class, the market has been categorized into anti-malarial, tetracycline antibiotics, anti-rheumatics, anti-arrhythmics, and analgesics & pain relievers. The anti-malarial segment holds the largest share of the cerebral malaria therapeutics market due to increasing incidence of malaria globally. The tetracycline antibodies segment is likely to witness high growth in the next few years driven by effective treatment/killing of the parasite causing malaria.
Based on distribution channel, the market has been classified into hospital pharmacies, retail pharmacies, drug store, online pharmacies, and others. The hospitals pharmacies segment held the largest share of the market due to easy access for outpatient department (OPD) patients to buy medicines. Online pharmacies are likely to witness lucrative growth during the forecast period due to increasing online purchase by patients and various discounts offered by online stores.
Browse more detail information about cerebral malaria therapeutics market:
Geographically, the cerebral malaria therapeutics market has been segmented into five major regions: North America (U.S. and Canada), Europe (Germany, France, U.K., etc.), Asia Pacific (Australia, China, Japan, India, etc.), Latin America (Brazil, Mexico, etc.), and Middle East &Africa (GCC Countries, South Africa, etc.). North America is the leading market for cerebral malaria therapeutics drugs in terms of revenue, followed by Europe. The U.S. holds the largest share of the market in the region.
Asia Pacific and Latin America are emerging markets, which are expected to witness strong growth during the forecast period from 2016 to 2014. Strong growth in these regions is attributed to increasing incidence of malaria, rising health care industries, and increase in government investment to develop health care infrastructure. The cerebral malaria therapeutics market in countries such as China, India, and Brazil is projected to expand at high growth rate during the forecast period due to increase in awareness among the population about malaria disease and its treatment.
Major players operating in the cerebral malaria therapeutics market include Quepharma, Cipla, Inc., Ipca Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Guilin Pharmaceutical (Shanghai) Co., Ltd., Novartis AG, Mylan Labs, Ajanta Pharma, Sanofi, and Astra Zeneca plc.
Please download sample copy of cerebral malaria therapeutics market report if you’d like to receive a soft copy of this brief summary.
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
Transparency Market Research
90 State Street,
NY – 12207
USA – Canada Toll Free 866-552-3453